NewsBenzingaReported Saturday, Incyte To Co-Fund Genmab’s Phase 1/2 Study Of Petosemtamab Combination In First-Line KRAS G12D-Mutated Metastatic Colorectal Cancer, Provide INCB161734 Clinical Supply Reported Saturday, Incyte To Co-Fund Genmab’s Phase 1/2 Study Of Petosemtamab Combination In First-Line KRAS G12D-Mutated Metastatic Colorectal Cancer, Provide INCB161734 Clinical Supply Benzinga 2026.10.26 07:07 (GMT+0) Open on Benzinga Other news Easterly Government Props Q3 FFO $0.78, Inline, Sales $93.611M Beat $92.168M Estimate Easterly Government Props Raises FY2026 FFO Guidance from $3.07-$3.13 to $3.08-$3.13 vs $3.10 Est Traders Are Pricing a 11% Swing In Intel Ahead of Earnings HC Wainwright & Co. Reiterates Buy on Journey Medical, Maintains $13 Price Target Strategy Gears Up to Report Q3 Financials — Crypto Bettors Expect the Bitcoin Hoarder to Beat Earnings Apple's $2,000 Foldable iPhone Sparks Buying Frenzy
Strategy Gears Up to Report Q3 Financials — Crypto Bettors Expect the Bitcoin Hoarder to Beat Earnings
